Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Bill Retains ANDA “Antibundling” Language “Livable” To GPhA

Executive Summary

Medicare prescription drug benefit legislation is likely to contain a modified version of the House bill's "antibundling" provision for generic drug applications following a Sept. 30 Capitol Hill meeting between the brand and generic drug industries

You may also be interested in...



GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel

Former FDA Chief Counsel Daniel Troy will once again be leading a team of lawyers with a drug regulatory focus

GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel

Former FDA Chief Counsel Daniel Troy will once again be leading a team of lawyers with a drug regulatory focus

FDA Guidance On ANDA Antibundling Statute Expected In February

The ANDA bundling and antibundling provisions of the Medicare law will be part of a "short guidance" that FDA expects to issue in February

Related Content

UsernamePublicRestriction

Register

PS042577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel